Responses
Clinical and epidemiological research
IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial
Compose a Response to This Article
Other responses
No responses have been published for this article.